Working with our partners in all sectors, Friends took ‘Breakthrough’ from concept, to scientific whitepaper, to bipartisan legislative solution, to a tool in full use by FDA to expedite the approval of multiple drugs in 13 months.
On Novemer 1, 2013, only a year after being signed into law, and 29 designations being announced, the first Breakthrough designation recieved full FDA Approval!
Below are the designations that have been announced so far:Breakthrough Designations Announced By Companies (Updated 1125/2013):
As knowledge about complex disease such as cancer and HIV/AIDS has expanded, researchers have been able to develop increasingly precise methods of treatment. Targeted therapies, a variety of drugs that targets specific molecular pathways, allow physicians and researchers to identify patients highly likely to respond to treatment. Frequently, these new drugs show major clinical activity and significant improvement over currently available treatment early in their development. In cases where new drugs show so much promise, and particularly in cases where existing treatment options are limited, the traditional multi-phase, sequential drug development process may not be appropriate.
Breakthrough Therapy (and Friends) in the News
FRIENDS OF CANCER RESEARCH
1800 M Street NW Suite 1050 | Washington, DC 20036